Human Virome Characterization Centers (U54 Clinical Trial Not Allowed)

The summary for the Human Virome Characterization Centers (U54 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Human Virome Characterization Centers (U54 Clinical Trial Not Allowed): The RFA will solicit applications for the Human Virome Program under the NIH Common Fund to establish multicomponent Virome Centers that will focus on the identification and characterization of the human virome in longitudinal and diverse cohorts across several body sites and tissues. The multicore structure of each center will allow for specialized and broad expertise in isolating viruses (circulating, proviral, integrated forms) and a coordinated, and comprehensive research program for recruiting diverse participants, collecting and analyzing many types of biospecimens, standardizing and analyzing center data, and addressing ethical, social and legal implications of human virome research. The Centers will also work collaboratively across the program consortium of separately awarded investigative teams in the coordination and management of consortium policies and practices. Similar to other U54 initiatives, the virome centers have unique objectives and specific review criteria and core specifications outlined in the RFA, and currently, there are no existing study sections with the necessary expertise to review this complex program.

Federal Grant Title:	Human Virome Characterization Centers (U54 Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-RM-23-019
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.310
CFDA Descriptions:	Information not provided
Current Application Deadline:	November 17th, 2023
Original Application Deadline:	November 17th, 2023
Posted Date:	September 13th, 2023
Creation Date:	September 13th, 2023
Archive Date:	December 23rd, 2023
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	September 14th, 2023

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-23-019.html
Grant Announcement Contact: NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets (R03 Clinical Trial No...; • Technologies and Assays for Therapeutic Genome Editing INDs (U01, Clinical Trial Not Allow...; • NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional); • NIH Directors Early Independence Awards (DP5 Clinical Trial Optional); • NIH Directors New Innovator Award Program (DP2 Clinical Trial Optional); • Using Metabolomics to Investigate Biological Pathways and Networks (R01); • Assay Development for High Throughput Molecular Screening (R21); • Membrane Protein Production and Structure Determination (R01)
More Grants from the National Institutes of Health: • Hazardous Materials Worker Health and Safety Training (U45 Clinical Trials Not Allowed); • Lasker Clinical Research Scholars Program (Si2/R00 Clinical Trial Optional); • Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed); • Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Opti...; • Advancing HIV service delivery through pharmacies and pharmacists (R01 Clinical Trial Opti...